ArticleBMC infectious diseases2025
Interactions of Mycoplasma genitalium (Mg) and human papillomavirus (HPV) infections among couples.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycoplasma genitalium is a sexually transmitted pathogen infecting the uterine cervix and causing pelvic inflammatory disease in women. Persistent high-risk human papillomavirus (HR-HPV) infections are important etiological agents in cervical and oral carcinogenesis. The potential interactions between M. genitalium- and HPV infections are incompletely studied.
methodsThis study included 329 women and 135 of their male partners in the prospective Finnish Family HPV study, followed up for three years. Genital and oral scrapings and blood samples were collected at baseline and 12-, 24-, and 36-month follow-up visits. HPV-L1 IgG-antibodies to HPV6/11/16/18/45 and M. genitalium IgG-antibodies to MgPa N-term and rMgPa were assayed by multiplex serology, and HPV genotyping was performed by Multiplex Genotyping. Statistical analyses were conducted using the χ2-test, likelihood ratio, or Fisher’s exact test for categorical variables, and nonparametric tests for continuous variables. Crude and adjusted odds ratios (ORs) with 95% confidence intervals (95% CI) were calculated using the logistic regression models.
resultsPersistent oral or genital HPV infections did not show any associations with the M. genitalium antibody levels. Incident oral HPV infections were significantly increased among women with high-levels of MgPa N-term antibodies, OR 4.14 (95%CI 1.10–15.52). M. genitalium antibodies were associated with an increased likelihood of seropositivity to HR-HPV during the follow-up, OR range from 2.66 to 4.62 (with 95%CI range of 1.01–11.00).
conclusionM. genitalium serology seems to be unrelated to outcomes of genital HPV infections but might increase the incidence of oral HPV infections and the likelihood of HPV seropositivity among women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.